Sepsis in the non-neutropenic host – Is there a need for molecular testing?
Prof. Michael Bauer, MD Jena University, Jena, Germany
Incorporating direct from whole blood diagnostics into clinical and antimicrobial stewardship practices
Dr. Cornelius (Neil) Clancy, University of Pittsburgh Medical Center, Pittsburgh, United States
Clinical experience with a bacteria panel and resistance markers direct from whole blood
Dr. Giulia De Angelis, Institute of Microbiology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
T2MR improves patient outcomes and guides therapy decisions in immunocompromised patients
Dr. Thomas Walsh, New York Presbyterian Hospital, New York City, United States
